You are here
P&T October 2019
New gene therapies, deeper insights into stem cells, and advances in imaging and artificial intelligence are making researchers, physicians, and some patients optimistic about retinal disease treatment.
Meta-analysis shows that DOACs with P2Y12 inhibitors were associated with lower bleeding rates than warfarin with triple antithrombotic therapy.
This review describes the inactive ingredients in recombinant pharmaceuticals and how they relate to dietary prohibitions for faith and other reasons.
Summaries of selected sessions from HFSA 2019: clinical effectiveness of sacubitril/valsartan; use of low-dose dopamine; the cost effectiveness of routine surveillance for organ rejection after heart transplant; inotrope therapy survival rates; and adherence rates of patients with multiple prescriptions.
CMS backs away from changes to Part D protected classes regulations.
Time to reassess patient-controlled analgesia.
A look at selinexor (Xpovio)for relapsed/refractorymultiple myeloma.
Erenumab (Aimovig) is the first FDA-approved migraine drug that targets the calcitonin gene-related peptide (CGRP).